The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 17, 2017
Filed:
Mar. 10, 2014
Applicants:
Dana-farber Cancer Institute, Inc., Boston, MA (US);
Genus Oncology, Llc, Chicago, IL (US);
Inventors:
Donald W. Kufe, Wellesley, MA (US);
Surender Kharbanda, Natick, MA (US);
Assignees:
Dana-Farber Cancer Institute, Inc., Boston, MA (US);
Genus Oncology, LLC, Chicago, IL (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/08 (2006.01); A61K 38/10 (2006.01); A61K 38/17 (2006.01); A61K 31/517 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
A61K 38/10 (2013.01); A61K 31/517 (2013.01); A61K 38/08 (2013.01); A61K 38/1709 (2013.01); A61K 39/39558 (2013.01);
Abstract
The treatment of human epidermal growth factor receptor 2-positive (HER2+) cancers using a combination of anti-mucin 1 (anti-MUC1) therapy and anti-human epidermal growth factor receptor 2 (anti-HER2) therapy is described, such as the treatment of trastuzamab-resistant cancers, both primary and acquired, using the same combination of agents.